Abstract
ABSTRACT Aim: Among the systemic therapeutic options available for metastatic breast cancer (MBC), non-pegylated liposomal doxorubicin (Myocet®, LED) limits anthracycline-related cardiotoxicity. This study aimed to analyse the therapeutic decision for choosing it vs. another chemotherapy drug (n-LED). Methods: A European, multicentre, prospective, observational study comparing at baseline LED vs. n-LED patients (pts) with confirmed MBC and scheduled 1st cycle of chemotherapy was performed in 8 countries (Austria, France, Germany, Ireland, Italy, Poland, Spain, United Kingdom). LED and n-LED pts were matched on centre, MBC chemotherapy line and time (comparisons used univariate logistic regression). Results: 1544 pts (772 in each group) were analysed (median age: 60 yrs; WHO performance status 0-1: 84%; HER2+ at initial diagnosis: 26%). 45% of both groups had 1st line therapy. LED was mainly given alone (39%), or combined with cyclophosphamide only (47%). 62% n-LED pts received monotherapy. Most of pts' clinical and disease characteristics were similar in both groups. However, HER2+ was less frequent in LED group (22% vs. 29%, p Conclusions: Even if the decision to use LED was not fully explained, some differences emerge across countries reflecting local specificities in MBC management. Cardiac risk remains the first motivation for oncologists to choose LED. Disclosure: G.G. Steger: Honoraria and travel grants from Cephalon and TEVA/Ratiopharm; H. Yosef: I acted as a member of advisory boards for Myocet; E. Albuisson: I receive remuneration from Cephalon France as expert member of the EOS Study Steering Committee; G. Batist: I have no financial interest in products or processes involved in my research, including stock ownership. I have served on Advisory Boards of Sanofi and Roche, each once in past year. I have investigator-initiated grants, with Pfizer, Bayer.; J. De Mouzon: I have been a compensated consultant for EOS study for protocol. I have no other conflict of interest; S. Maumus-Robert: I am an employee of ClinSearch, a contract research organisation which was contracted by Cephalon France/TEVA for the set up and management of the EOS study; M.S. Aapro: Dr Aapro is/was consultant & received lecture honoraria: Amgen/GSK/Helsinn/Hospira/Novartis/Merck/Merck Serono/Pfizer/Pierre; Fabre/Roche/Sandoz/Teva/Vifor; is/was consultant: Astellas/BMS/Celgene/Pharmacosmos; received lecture honoraria: Sanofi Aventis. All other authors have declared no conflicts of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
